Cryoport, Inc. (CYRX) Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Cryoport, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences industry, with a strategic focus on the cell and gene therapy (CGT) market. The company operates two primary reportable segments: Life Sciences Services (logistics, storage, and bioservices) and Life Sciences Products (cryogenic systems and equipment). A significant strategic shift occurred in June 2025 with the divestiture of the CRYOPDP courier business to DHL, which is now classified as discontinued operations.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $96,769 |
| Gross Margin | $44,737 (46.2% of revenue) |
| Loss from Continuing Operations | $(17,687) |
| Net Loss | $(18,799) |
| Net Loss Attributable to Common Stockholders | $(22,799) |
| Adjusted EBITDA (Continuing Ops) | $(236) |
| Cash and Cash Equivalents | $269,267 |
| Short-term Investments | $127,426 |
| Convertible Senior Notes (Current Portion) | $185,687 |
| Working Capital | $239,167 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 11.9% ($10.3 million) compared to the six months ended June 30, 2025. Life Sciences Services revenue grew 16.2%, driven by BioLogistics Solutions (+14.6%) and BioStorage/BioServices (+22.8%). Life Sciences Products revenue grew 6.7%.
- Discontinued Operations Impact: The prior year period included a significant gain from the sale of the CRYOPDP business ($115.6 million net income from discontinued operations). The current period reflects no such gain, resulting in a reported Net Loss of $(18.8) million compared to Net Income of $96.9 million in the prior year.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased by 14.0% ($6.8 million), primarily due to the absence of a $5.2 million contingent consideration release in the prior year and increased wages. Engineering and development expenses rose 8.8% due to investments in AI and cryogenic technology.
- Investment Income: Investment income surged 104.7% to $6.2 million, offsetting some operating losses.
- Cash Flow: Net cash provided by operating activities turned positive at $4.9 million, compared to a use of $11.7 million in the prior year, driven by non-cash adjustments and working capital management.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring operating losses in the near term while investing in supply chain initiatives and technology. The company supports 779 clinical trials globally (94 in Phase 3) and 22 commercial therapies, viewing the transition of clinical programs to commercial scale as a key growth driver.
- Liquidity: As of June 30, 2026, the company holds approximately $396.7 million in cash, cash equivalents, and short-term investments. Management believes these resources, combined with projected cash flows, are sufficient to meet operational requirements and repay the $186.2 million Convertible Senior Notes due in December 2026 for at least the next 12 months.
- Risks:
- Debt Maturity: Significant repayment of $186.2 million in Convertible Senior Notes is due in December 2026.
- Market Volatility: Exposure to foreign currency fluctuations (EUR, GBP, CNY) and interest rate changes affecting investment portfolio fair value.
- Integration: Risks associated with the strategic partnership with DHL following the CRYOPDP divestiture.
- Regulatory: Dependence on regulatory approvals for client therapies and compliance with global supply chain regulations.
- Unusual Items: The filing includes a $3.7 million correction to prior period goodwill impacting the gain on disposal of the CRYOPDP business, which was reclassified to discontinued operations.
Investor Verification Checklist
- Verify the company's ability to refinance or repay the $186.2 million Convertible Senior Notes maturing in December 2026.
- Monitor the conversion of Series C Preferred Stock (200,000 shares outstanding) and its impact on common equity dilution.
- Assess the sustainability of investment income ($6.2 million YTD) as a buffer against operating losses, given market volatility.
- Review the stock repurchase program status; $63.9 million remains available under the 2024 program, though no shares were repurchased in the current period.
- Track the growth of Commercial Cell and Gene Therapy revenue as a percentage of total revenue to validate the long-term growth thesis.